Katsi Vasiliki, Manta Eleni, Fragoulis Christos, Tsioufis Konstantinos
First Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens Medical School, 114 Vasilissis Sofias Avenue, 11527 Athens, Greece.
Biomedicines. 2024 Oct 10;12(10):2293. doi: 10.3390/biomedicines12102293.
Obesity and hypertension have become an international health issue, with detrimental consequences on patients. Obesity and hypertension share common pathophysiological mechanisms, such as overactivity of the renin-angiotensin-aldosterone and the sympathetic nervous systems, insulin resistance, and disruption of the leptin pathway. Approved therapies for obesity and overweight include phentermine/topiramate, orlistat, naltrexone/bupropion, the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide, tirzepatide, and bariatric surgery. This review gives the clinical data in a thorough manner and explains in detail how each of the previously mentioned therapies affects blood pressure levels.
肥胖和高血压已成为一个国际健康问题，对患者产生有害影响。肥胖和高血压具有共同的病理生理机制，如肾素-血管紧张素-醛固酮系统和交感神经系统过度活跃、胰岛素抵抗以及瘦素途径紊乱。已获批的肥胖和超重治疗方法包括苯丁胺/托吡酯、奥利司他、纳曲酮/安非他酮、胰高血糖素样肽-1受体激动剂利拉鲁肽和司美格鲁肽、替尔泊肽以及减肥手术。本综述全面给出了临床数据，并详细解释了上述每种治疗方法如何影响血压水平。
